| 1 |
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Steven P. Marso, Stephen Charles Bain, Agostino Consoli et al. · New England Journal of Medicine
Open access |
16 Sep 2016 |
6,902 |
| 2 |
Once-Weekly Semaglutide in Adults with Overweight or Obesity
John P.H. Wilding, Rachel Louise Batterham, Salvatore Calanna et al. · New England Journal of Medicine
Open access |
10 Feb 2021 |
5,049 |
| 3 |
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Juan P. Frías, Melanie J. Davies, Julio Rosenstock et al. · New England Journal of Medicine
Open access |
25 Jun 2021 |
2,029 |
| 4 |
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials
Naveed A. Sattar, Matthew M.Y. Lee, Søren Lund Kristensen et al. · The Lancet Diabetes & Endocrinology
ReviewOpen access |
20 Aug 2021 |
1,590 |
| 5 |
Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
John B. Buse, Julio Rosenstock, Giorgio Sesti et al. · The Lancet
|
9 Jun 2009 |
1,505 |
| 6 |
The Treat-to-Target Trial
Matthew C. Riddle, Julio Rosenstock, John Gerich et al. · Diabetes Care
Open access |
Nov 2003 |
1,482 |
| 7 |
Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial
Melanie J. Davies, Louise Færch, Ole Kleist Jeppesen et al. · The Lancet
Open access |
Mar 2021 |
1,384 |
| 8 |
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity
Domenica Rubino et al. · JAMA
Open access |
23 Mar 2021 |
1,377 |
| 9 |
Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Patients With Type 2 Diabetes Treated With Metformin and a Sulfonylurea
David M. Kendall, Matthew C. Riddle, Julio Rosenstock et al. · Diabetes Care
|
May 2005 |
1,180 |
| 10 |
Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk
Julio Rosenstock, Vlado Perkovic, Odd Erik Johansen et al. · JAMA
Open access |
12 Nov 2018 |
1,099 |
| 11 |
Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension
John P.H. Wilding, Rachel Louise Batterham, Melanie J. Davies et al. · Diabetes Obesity and Metabolism
Open access |
19 Apr 2022 |
1,066 |
| 12 |
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
Julio Rosenstock, Carol Wysham, Juan P. Frías et al. · The Lancet
|
27 Jun 2021 |
1,057 |
| 13 |
Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes
Domenica M. Rubino et al. · JAMA
Open access |
11 Jan 2022 |
937 |
| 14 |
Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study
on behalf of the NN8022-1923 Investigators, Thomas A. Wadden, Priscilla A. Hollander et al. · International Journal of Obesity
|
Jul 2013 |
833 |
| 15 |
Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes
Hertzel C. Gerstein, Naveed A. Sattar, Julio Rosenstock et al. · New England Journal of Medicine
Open access |
28 Jun 2021 |
824 |
| 16 |
Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial
Julio Rosenstock, Michael M. Tuchman, Linda LaMoreaux et al. · Pain
|
16 Jun 2004 |
730 |
| 17 |
NEW-ONSET DIABETES AFTER TRANSPLANTATION: 2003 INTERNATIONAL CONSENSUS GUIDELINES1
Jaime A. Davidson, Alan H. Wilkinson, Jacques Dantal et al. · Transplantation
|
May 2003 |
679 |
| 18 |
Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors
Julio Rosenstock, Ele Ferrannini · Diabetes Care
|
10 Aug 2015 |
666 |
| 19 |
Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes
Julio Rosenstock, Steven E. Kahn, Odd Erik Johansen et al. · JAMA
Open access |
19 Sep 2019 |
617 |
| 20 |
METABOLIC COUPLING FACTORS IN PANCREATIC β-CELL SIGNAL TRANSDUCTION
Christopher B. Newgard, Julie McGarry · Annual Review of Biochemistry
|
Jun 1995 |
532 |
| 21 |
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study
Julio Rosenstock, Ronald Brazg, Paula J. Andryuk et al. · Clinical Therapeutics
|
Oct 2006 |
516 |
| 22 |
Use of Twice-Daily Exenatide in Basal Insulin–Treated Patients With Type 2 Diabetes
John B. Buse, Richard M. Bergenstal, Leonard C. Glass et al. · Annals of Internal Medicine
|
18 Jan 2011 |
508 |
| 23 |
Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes
Melanie J. Davies, Thomas Rudolf Pieber, Marie‐Louise Hartoft‐Nielsen et al. · JAMA
Open access |
17 Oct 2017 |
498 |
| 24 |
PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes
Vanita R. Aroda et al. · Diabetes Care
Open access105 authors |
11 Jun 2019 |
485 |
| 25 |
Basal Insulin Therapy in Type 2 Diabetes
Julio Rosenstock, Sherwyn Leon Schwartz, Charles M. Clark et al. · Diabetes Care
Open access |
Apr 2001 |
482 |
| 26 |
Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea
Guntram Schernthaner, Jorge Luiz Gross, Julio Rosenstock et al. · Diabetes Care
Open access |
6 Apr 2013 |
482 |
| 27 |
Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial
Helena W. Rodbard et al. · Diabetes Care
Open access118 authors |
17 Sep 2019 |
464 |
| 28 |
A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes
Julio Rosenstock, Melanie J. Davies, Philip Home et al. · Diabetologia
Open access |
15 Jan 2008 |
448 |
| 29 |
Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-On to Metformin in Subjects With Type 2 Diabetes
Julio Rosenstock, Naresh Aggarwal, David Polidori et al. · Diabetes Care
Open access |
10 Apr 2012 |
423 |
| 30 |
Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea
Julio Rosenstock, Dale Allison, Andreas L. Birkenfeld et al. · JAMA
Open access |
23 Mar 2019 |
414 |
| 31 |
Effects of Dapagliflozin, an SGLT2 Inhibitor, on HbA1c, Body Weight, and Hypoglycemia Risk in Patients With Type 2 Diabetes Inadequately Controlled on Pioglitazone Monotherapy
Julio Rosenstock, Marisa L. Vico, Wei Li et al. · Diabetes Care
Open access |
24 Mar 2012 |
408 |
| 32 |
Lipoapoptosis in Beta-cells of Obese Prediabeticfa/fa Rats
Michio Shimabukuro, Moritake Higa, Yan-Ting Zhou et al. · Journal of Biological Chemistry
Open access |
Dec 1998 |
395 |
| 33 |
Diabetes and breast cancer risk: a meta-analysis
Peter A. Boyle, Mathieu Boniol, Alice Koechlin et al. · British Journal of Cancer
ReviewOpen access |
20 Sep 2012 |
381 |
| 34 |
Essentiality of circulating fatty acids for glucose-stimulated insulin secretion in the fasted rat.
Daniel T. Stein, Victoria Esser, Brent E Stevenson et al. · Journal of Clinical Investigation
Open access |
15 Jun 1996 |
379 |
| 35 |
Reduced Hypoglycemia Risk With Insulin Glargine
Julio Rosenstock, GEORGE E. DAILEY, Massimo Massi‐Benedetti et al. · Diabetes Care
|
Apr 2005 |
372 |
| 36 |
Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From aDiabetes CareEditors’ Expert Forum
William T. Cefalu, Sanjay Kaul, Hertzel C. Gerstein et al. · Diabetes Care
Open access |
20 Dec 2017 |
370 |
| 37 |
Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections of Insulin in Obese Inadequately Controlled Type 2 Diabetes
Julio Rosenstock, Ante Jelaska, Guillaume Frappin et al. · Diabetes Care
Open access |
12 Jun 2014 |
368 |
| 38 |
Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials
Julio Rosenstock, Jan Marquard, Lori M. Laffel et al. · Diabetes Care
|
4 Oct 2018 |
364 |
| 39 |
A Randomized Trial of Rosiglitazone Therapy in Patients With Inadequately Controlled Insulin-Treated Type 2 Diabetes
Philip Raskin, Marc Rendell, Matthew C. Riddle et al. · Diabetes Care
|
Jul 2001 |
346 |
| 40 |
2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial
Baptist Gallwitz, Julio Rosenstock, Thomas Rauch et al. · The Lancet
|
27 Jun 2012 |
343 |
| 41 |
The Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the Circulation: Results From Short-term Pharmacokinetic and 12-Week Dose-Ranging Studies
John B. Buse, Ralph Anthony DeFronzo, Julio Rosenstock et al. · Diabetes Care
|
18 Aug 2015 |
330 |
| 42 |
Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study
Richard E. Pratley, Michael Albrecht Nauck, Anthony H Barnett et al. · The Lancet Diabetes & Endocrinology
|
5 Feb 2014 |
327 |
| 43 |
Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial
Alan J. Garber, Allen Bennett King, Stefano Del Prato et al. · The Lancet
|
Apr 2012 |
326 |
| 44 |
Set points, settling points and some alternative models: theoretical options to understand how genes and environments combine to regulate body adiposity
John Roger Speakman et al. · Disease Models & Mechanisms
Open access |
Nov 2011 |
323 |
| 45 |
The 11-β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor INCB13739 Improves Hyperglycemia in Patients With Type 2 Diabetes Inadequately Controlled by Metformin Monotherapy
Julio Rosenstock, Salomon Banarer, Vivian Andrew Fonseca et al. · Diabetes Care
Open access |
22 Apr 2010 |
318 |
| 46 |
Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes
Tina Vilsbøll, Julio Rosenstock, Hannele Yki-Järvinen et al. · Diabetes Obesity and Metabolism
Open access |
6 Nov 2009 |
305 |
| 47 |
Obesity, Diabetes, and Increased Cancer Progression
Dae-Seok Kim, Philipp E. Scherer · Diabetes & Metabolism Journal
Open access |
22 Nov 2021 |
302 |
| 48 |
Safety and efficacy of linagliptin as add‐on therapy to metformin in patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled study
Marja‐Riitta Taskinen, Julio Rosenstock, Ilkka Tamminen et al. · Diabetes Obesity and Metabolism
|
18 Oct 2010 |
294 |
| 49 |
Dual Add-on Therapy in Type 2 Diabetes Poorly Controlled With Metformin Monotherapy: A Randomized Double-Blind Trial of Saxagliptin Plus Dapagliflozin Addition Versus Single Addition of Saxagliptin or Dapagliflozin to Metformin
Julio Rosenstock, Lars Lindgaard Hansen, Pamela Zee et al. · Diabetes Care
|
28 Oct 2014 |
290 |
| 50 |
Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin
Matthew C. Riddle, Ronnie Aronson, Philip Home et al. · Diabetes Care
Open access |
30 Apr 2013 |
289 |